Fresenius Medical Care AG (ETR:FME - Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of €42.22 ($45.89) and traded as high as €45.89 ($49.88). Fresenius Medical Care shares last traded at €45.40 ($49.35), with a volume of 439,037 shares.
Fresenius Medical Care Stock Up 0.9 %
The stock's fifty day moving average is €45.49 and its two-hundred day moving average is €42.39. The company has a current ratio of 1.37, a quick ratio of 0.80 and a debt-to-equity ratio of 82.24. The company has a market capitalization of $13.59 billion, a PE ratio of 20.62, a P/E/G ratio of 0.42 and a beta of 0.86.
Fresenius Medical Care Company Profile
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Recommended Stories
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.